On March 30, 2026, PepGen Inc. (Nasdaq: PEPG) announced promising topline results from the lowest dose (5 mg/kg) cohort of its ongoing Phase 2 FREEDOM2 study, which evaluates PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). The study demonstrated favorable safety and efficacy outcomes, with PGN-EDODM1 being generally well-tolerated. Notably, all adverse events reported were mild or moderate, with no serious adverse events observed. The study included eight patients, with a mean splicing correction of 7.3% in the treatment group compared to 6.8% in the placebo group. Excluding one outlier, the treatment group showed a mean splicing correction of 22.9%. Additionally, promising trends were observed in the video hand opening test (vHOT) among patients treated with PGN-EDODM1. The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026, with sufficient cash expected to fund operations into the second half of 2027. A conference call is scheduled for today at 4:30 p.m. ET to discuss these results further.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.